Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

Bibliographic Details
Main Authors:	Yee, Brittany E, Nguyen, Nghia H, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Format:	Online
Language:	English
Published:	BMJ Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780041/

Similar Items

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
by: Nguyen, Nghia H, et al.
Published: (2016)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
by: Sarkar, Souvik, et al.
Published: (2015)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
by: Obed, Aiman, et al.
Published: (2016)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
by: Yee, Brittany E, et al.
Published: (2015)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
by: Khemichian, Saro, et al.
Published: (2015)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
by: Ascha, Mustafa, et al.
Published: (2015)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
by: Zhang, Bing, et al.
Published: (2015)

Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
by: Papadopoulos, Nikolaos, et al.
Published: (2016)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
by: Gaetano, John N
Published: (2014)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
by: Eyre, Zachary W., et al.
Published: (2016)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
by: Maruyama, Anna, et al.
Published: (2016)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker, David R, et al.
Published: (2015)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
by: Issa, D., et al.
Published: (2016)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
by: McQuaid, Thomas, et al.
Published: (2015)

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients
by: Patel, Nimish, et al.
Published: (2015)

Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report
by: Ende, Alexander R., et al.
Published: (2015)

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients
by: Ajlan, A., et al.
Published: (2016)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
by: Kanda, Tatsuo, et al.
Published: (2014)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018-09-01)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
by: Kayali, Zeid, et al.
Published: (2014)

Sofosbuvir and daclatasvir
by: Hessel, Marleen H. M., et al.
Published: (2016)

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir
by: Safadi, Rifaat, et al.
Published: (2016)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
by: Leen Vijgen, et al.
Published: (2017-05-01)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
by: Do, Albert, et al.
Published: (2015)

Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States
by: Vutien, Philip, et al.
Published: (2016)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram, Vinay, et al.
Published: (2016)

Simeprevir for the treatment of hepatitis C virus infection
by: Izquierdo, Laure, et al.
Published: (2014)

Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
by: Andreas Walker, et al.
Published: (2017-06-01)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
by: Watanabe, Takao, et al.
Published: (2016)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
by: Leleu, H, et al.
Published: (2015)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
by: Wong, Carrie R, et al.
Published: (2016)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
by: Asselah, Tarik, et al.
Published: (2016)

Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis
by: Hoang, Joseph K., et al.
Published: (2016)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
by: Ouwerkerk-Mahadevan, Sivi, et al.
Published: (2015)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
by: Ouwerkerk-Mahadevan, Sivi, et al.
Published: (2015)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
by: Lawitz, Eric, et al.
Published: (2015)

Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report
by: Seifert, Leon Louis, et al.
Published: (2016)

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care
by: Vu, Vinh D, et al.
Published: (2015)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
by: Garbuglia, Anna Rosa, et al.
Published: (2014)